Close Menu

Cancer Biomarkers

News on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse.

The company is testing out its immune-stimulating antibody conjugate platform technology, hitching its proprietary molecule to trastuzumab.

A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.

In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.

The approval limits the drug's use to patients who are refractory or intolerant to standard-of-care treatments and contains warnings about the risk of interstitial lung disease.

Radboud University Medical Center researchers developed and validated the single-molecule molecular inversion probe-centered workflow for more efficient BRCA1/2 testing.

The Chinese drug evaluation agency has granted the investigational new drug clinical trial authorization to taletrectinib in NRTK- and ROS1-mutated cancer patients.

Breast cancer patients with certain germline risk variants were more responsive to the chemotherapy combinations tested in a randomized trial.

The drug, JNJ-6372, is currently being studied in non-small cell lung cancer patients with EGFR exon 20 insertion mutations.

RMC-4630 will be investigated in combination with an investigational ERK inhibitor in RAS-mutated solid tumors.

The precision oncology startup is gearing up to enroll patients in its tissue-agnostic Phase I/II trial for its investigational new drug BDTX-189.

Pages